Prosecution Insights
Last updated: November 12, 2026
Application No. 19/353,597

SEVEN-COMPONENT ANTIGEN AFRICAN SWINE FEVER SUBUNIT VACCINE

Non-Final OA §112
Filed
Oct 08, 2025
Priority
Apr 10, 2023 — CN 2023103733573 +1 more
Examiner
GRIZER, CASSANDRA SENN
Art Unit
1672
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Lanzhou Veterinary Research Institute Chinese Academy Of Agricultural Sciences
OA Round
1 (Non-Final)
75%
Grant Probability
Favorable
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
9 granted / 12 resolved
+15.0% vs TC avg
Strong +47% interview lift
Without
With
+46.7%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
41 currently pending
Career history
59
Total Applications
across all art units

Office Action

§112
DETAILED NOTICE Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Acknowledgment is made of Applicant’s claims foreign priority under 35 U.S.C. 119 (a)-(d). The certified copy has been filed on 21 October 2025. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Claim Status Claims 1-10 are pending all of which have been considered on the merits. Claim Objections Claims 2, 4, 6, and 10 are objected to because of the following informalities: “The ASFV antigen protein combination according to claim 1” should read “The ASFV antigen protein combination of claim 1”. Claim 3 is objected to because of the following informalities: “The ASFV antigen protein combination according to claim 2” should read “The ASFV antigen protein combination of claim 2”. Claim 5 is objected to because of the following informalities: “The ASFV antigen protein combination according to claim 4” should read “The ASFV antigen protein combination of claim 4”. Claim 7 is objected to because of the following informalities: “The ASFV antigen protein combination according to claim 6” should read “The ASFV antigen protein combination of claim 6”. Claims 8-9 are objected to because of the following informalities: “The ASFV antigen protein combination according to claim 7” should read “The ASFV antigen protein combination of claim 7”. Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-10 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The phrase “set forth in” in claim 1 (lines 10-21) is indefinite. The phrase is not defined in the claims or Specification. One of ordinary skill would not be able to reasonably ascertain the invention. The dependent claims do not add additional clarity and, therefore, are also indefinite. For purposes of compact prosecution and applying prior art, the claims were broadly interpreted to require a protein comprising the amino acid sequence the SEQ ID NOs. Claim 1 is unclear due to lack of antecedent basis for SEQ ID NOs: 17, 19, and 21. Previously in the claim only “a fusion protein of an extracellular domain of a P22 protein and an extracellular domain of a P17 protein” is defined which correlates to SEQ ID NO: 23. It is unclear if “the fragments” are also extracellular domains as “the fragments” are not previously mentioned or defined. Claims 1 and 4-5 are indefinite because it is unclear how the ratios are determined i.e. mass, molar. The ratios are not clearly labeled or defined for one of skill in the art to determine how to measure the ratios between the proteins. It is noted that any interpretation of the claims set forth above does not relieve Applicant of the responsibility of responding to this rejection. If the actual interpretation of the claims is different than that posited by the Examiner, additional rejection and art may be readily applied in a subsequent final Office action. Conclusion NO CLAIMS ARE ALLOWED Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cassandra Senn Grizer whose telephone number is (571)272-2292. The examiner can normally be reached M-Th 0630 - 1700 ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Thomas J. Visone can be reached at 571-270-0684. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CASSANDRA SENN GRIZER/ Examiner, Art Unit 1672 /THOMAS J. VISONE/ Supervisory Patent Examiner, Art Unit 1672
Read full office action

Prosecution Timeline

Oct 08, 2025
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767702
ANTI-VARICELLA-ZOSTER VIRUS ANTIBODY AND USE THEREOF
3y 1m to grant Granted Oct 20, 2026
Patent 12741995
UBIQUITIN VARIANT WITH HIGH AFFINITY FOR BINDING 53BP1 REDUCES THE AMOUNT OF AAV NEEDED TO ACHIEVE HIGH RATES OF HDR
3y 1m to grant Granted Sep 22, 2026
Patent 12728160
VACCINE USING M2/BM2-DEFICIENT INFLUENZA VECTORS
3y 7m to grant Granted Sep 08, 2026
Patent 12653851
ISOLATED RECOMBINANT ONCOLYTIC ADENOVIRUSES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF FOR DRUGS FOR TREATMENT OF TUMORS AND/OR CANCERS
2y 9m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 4 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
75%
Grant Probability
99%
With Interview (+46.7%)
Low
PTA Risk
Based on 12 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month